Lifileucel
- Generic Name
- Lifileucel
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2306267-74-1
- Unique Ingredient Identifier
- R0835E18NH
- Associated Conditions
- -
- Associated Therapies
- -
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Immatics US, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT06743126
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT06481592
- Locations
- 🇺🇸
Allegheny Health, Pittsburgh, Pennsylvania, United States
🇺🇸UofL Health - Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Shanghai Juncell Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT06473961
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-06-15
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT05903937
Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Vastra Gotaland Region
- Target Recruit Count
- 6
- Registration Number
- NCT04812470
- Locations
- 🇸🇪
Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden
Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma
- First Posted Date
- 2015-02-10
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Iovance Biotherapeutics, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT02360579
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇬🇧Royal Marsden NHS Trust, London, England, United Kingdom
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath